Evidence map›Paper›PMID 22702509›Full record

ArticleClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2012

Lung effects of inhaled corticosteroids in a rhesus monkey model of childhood asthma.

C G Plopper, J P Joad, L A Miller, E S Schelegle, M V Fanucchi, L S Van Winkle, N K Tyler, M V Avdalovic, M J Evans, W L Lasley and 8 more

Open access · greenAbstract read
In one paragraph

Article in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.2field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 14 citations in OpenAlex.

  1. Trial
  2. Review
  3. Review
  4. Review
  5. Newly divided eosinophils limit ozone-induced airway hyperreactivity in nonsensitized guinea pigs.American journal of physiology. Lung cellular and molecular physiology · 2017
    Article
  6. Review
  7. Why primate models matter.American journal of primatology · 2014
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 1 institution in 1 country.

C G PlopperRespiratory Diseases Unit, California National Primate Research Center, University of California, One Shields Ave, Davis, CA 95616, USA. cgplopper@ucdavis.edu
J P Joad
L A Miller
E S Schelegle
M V Fanucchi
L S Van Winkle
N K Tyler
M V Avdalovic
M J Evans
W L Lasley
A R Buckpitt
K E Pinkerton
B K Tarkington
S Davis
S J Nishio
L J Gershwin
R Wu
D M Hyde
University of California, Davis · US

Funding

ZONA PELLUCIDA PEPTIDES AS IMMUNOCONTRACEPTIVE ANTIGENSP51RR000169 · NCRR · UNIVERSITY OF CALIFORNIA DAVIS · PI HYDE, DALLAS MELVIN · 1985 to 2011
$126.2M
ROLE OF EPITHELIAL CELLS IN OZONE-NITROGEN DIOXIDE INTERACTIONP01ES000628 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI WU, REEN · 1985 to 2010
$12.5M
NIEHS Center for Health Effects of AgrochemicalsP30ES005707 · NIEHS · UNIVERSITY OF CALIFORNIA DAVIS · PI MATSUMURA, FUMIO NONE · 1992 to 2006
$9.9M
Early Immune Events in Childhood AsthmaR01HL081286 · NHLBI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI MILLER, LISA A · 2006 to 2009
$1.2M
MECHANISMS OF OXIDANT INDUCED LYMPHOCYTE REGULATIONF32ES005707 · NIEHS · WADSWORTH CENTER · PI KRIEGER, JIM A · 1995 to 1996
–
NCRR NIH HHS P51 RR000169NCRR NIH HHS RR00169NHLBI NIH HHS R01 HL081286NIEHS NIH HHS F32 ES005707NIEHS NIH HHS P01 ES000628NIEHS NIH HHS P01 ES00628NIEHS NIH HHS P30 ES005707
6 · The paper itself

Abstract

backgroundThe risks for infants and young children receiving inhaled corticosteroid (ICS) therapy are largely unknown. Recent clinical studies indicate that ICS therapy in pre-school children with symptoms of asthma result in decreased symptoms without influencing the clinical disease course, but potentially affect postnatal growth and development. The current study employs a primate experimental model to identify the risks posed by ICS therapy.

objectiveTo (1) establish whether ICS therapy in developing primate lungs reverses pulmonary pathobiology associated with allergic airway disease (AAD) and (2) define the impact of ICS on postnatal lung growth and development in primates.

methodsInfant rhesus monkeys were exposed, from 1 through 6 months, to filtered air (FA) with house dust mite allergen and ozone using a protocol that produces AAD (AAD monkeys), or to FA alone (Control monkeys). From three through 6 months, the monkeys were treated daily with ICS (budesonide) or saline.

resultsSeveral AAD manifestations (airflow restrictions, lavage eosinophilia, basement membrane zone thickening, epithelial mucin composition) were reduced with ICS treatment, without adverse effects on body growth or adrenal function; however, airway branching abnormalities and intraepithelial innervation were not reduced. In addition, several indicators of postnatal lung growth and differentiation: vital capacity, inspiratory capacity, compliance, non-parenchymal lung volume and alveolarization, were increased in both AAD and Control monkeys that received ICS treatment. CONCLUSIONS AND CLINICAL RELEVANCE: Incomplete prevention of pathobiological changes in the airways and disruption of postnatal growth and differentiation of airways and lung parenchyma in response to ICS pose risks for developing primate lungs. These responses also represent two mechanisms that could compromise ICS therapy's ability to alter clinical disease course in young children.

Indexed as

AsthmaLungAdrenal Cortex HormonesAllergensAnimalsAntigens, DermatophagoidesChildChild, PreschoolDisease Models, AnimalFemaleHumansInfantInfant, NewbornMacaca mulattaMaleAdrenal Cortex HormonesAllergensAntigens, Dermatophagoides

Identifiers

PMID22702509
PMCPMC3913647
OpenAlexW2076214020

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.